Research Analysts Offer Predictions for ANI Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Investment analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for shares of ANI Pharmaceuticals in a research report issued on Wednesday, June 26th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will post earnings per share of $0.75 for the quarter, down from their previous estimate of $0.82. HC Wainwright currently has a “Buy” rating and a $94.00 price target on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.34 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ FY2024 earnings at $3.34 EPS.

ANIP has been the topic of several other research reports. Capital One Financial started coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target on the stock. Truist Financial raised their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Guggenheim restated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $82.75.

ANI Pharmaceuticals Trading Up 2.0 %

Shares of NASDAQ ANIP opened at $65.49 on Thursday. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 40.93 and a beta of 0.81. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The stock’s 50 day simple moving average is $64.28 and its 200 day simple moving average is $61.59.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.16. The business had revenue of $137.43 million for the quarter, compared to the consensus estimate of $125.01 million. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%.

Insider Activity

In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the transaction, the senior vice president now owns 253,226 shares in the company, valued at $17,029,448.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other ANI Pharmaceuticals news, insider Christopher Mutz sold 2,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $61.61, for a total value of $123,220.00. Following the transaction, the insider now owns 83,277 shares in the company, valued at $5,130,695.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares in the company, valued at approximately $17,029,448.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,688 shares of company stock worth $11,408,863. 12.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Boston Partners purchased a new position in ANI Pharmaceuticals in the first quarter valued at about $606,000. Hancock Whitney Corp bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $360,000. California State Teachers Retirement System boosted its stake in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after acquiring an additional 233 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $289,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of ANI Pharmaceuticals by 7.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company’s stock worth $900,000 after acquiring an additional 909 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.